“…There is increasing evidence in the literature for skeletal neuromuscular involvement in the genesis as well as the prevention of Parkinson-like features induced by chemical agents that are recommended for screening procedures in the evaluation of antiParkinson drugs (Cahen & Lynes, 1951;Everett, Blockus & Shepperd, 1956;Ganguly, 1976;Das & Ganguly, 1977;Das, Ganguly & Vedasiromoni, 1978;Ganguly, Nath, Ross & Vedasiromoni, 1978; Ganguly & Das, 1979). Of these agents, the muscarinic agonist oxotremorine (Oxo-T), is unique in producing the typical features of Parkinson's disease (Friedman & Everett, 1964;Jenden, 1968).…”